Amrita Krishnan, MD

Panelists discuss how multiple myeloma support resources range from formal organizations like the International Myeloma Foundation and Multiple Myeloma Research Foundation to online patient communities, hospital-based support groups, and specialized social media networks, with advice for newly relapsed patients emphasizing the importance of allowing emotional processing before taking action, seeking second opinions from myeloma specialists, asking detailed questions about all available options including clinical trials, connecting with patients who’ve undergone similar treatments, maintaining hope amid setbacks, and recognizing that relapses, while challenging, often open doors to novel therapeutic approaches that can effectively control the disease for extended periods.

Panelists discuss how caregivers supporting loved ones with late-line relapsed/refractory multiple myeloma (RRMM) should prioritize both patient and self-care by establishing sustainable support systems, maintaining open communication with the health care team, educating themselves about treatment options while acknowledging emotional boundaries, creating practical organizational systems for medication management and appointment tracking, seeking respite care when needed, connecting with caregiver support groups for shared experiences, participating in decision-making without overshadowing the patient’s voice, preparing contingency plans for complications, and finding moments of normalcy and joy amid the challenges of advanced disease management.

Panelists discuss how effective communication with medical teams in advanced multiple myeloma requires proactive strategies including preparing prioritized question lists before appointments, bringing a designated note-taking advocate to consultations, utilizing patient portals for nonurgent concerns, clearly articulating quality of life impacts rather than just symptom presence, requesting dedicated time for treatment planning discussions, recording conversations (with permission) for later review, maintaining symptom diaries with specific details, and establishing relationships with nurse navigators who can facilitate more timely responses—approaches that collectively ensure patient needs are comprehensively addressed despite the complex nature of late-line treatment decisions.

Panelists discuss how patients and caregivers at the late-line treatment stage commonly struggle with profound concerns about diminishing treatment options, increased uncertainty about prognosis, managing complex and often cumulative side effects, financial toxicity from years of therapy, caregiver burnout, practical challenges of more frequent hospitalizations, anxiety about becoming refractory to novel agents, navigating clinical trial eligibility, maintaining hope while being realistic and balancing aggressive treatment approaches with quality of life considerations as therapeutic choices narrow.

Panelists discuss how lifestyle modifications have become crucial coping strategies for managing multiple myeloma symptoms and treatment side effects, with patients reporting benefits from structured exercise regimens tailored to their energy levels, anti-inflammatory dietary approaches, mindfulness practices and meditation for pain management, consistent sleep hygiene routines, strategic activity pacing throughout the day, hydration protocols, complementary therapies like acupuncture or massage and intentional social engagement—approaches that, while not replacing medical interventions, significantly enhance quality of life and resilience throughout the treatment journey.

Panelists discuss how quality of life priorities shift in late-line multiple myeloma treatment, with patients emphasizing the importance of maintaining independence in daily activities, preserving cognitive function, managing pain effectively, minimizing treatment-related side effects that impact social engagement, balancing treatment schedules to allow for meaningful family time and personal milestones and finding psychological peace through spirituality or support systems—ultimately revealing that while disease control remains critical, the ability to live with purpose and dignity increasingly shapes treatment decisions as patients progress through multiple therapy lines.

Panelists discuss how balancing treatment effectiveness with quality of life in late-line multiple myeloma therapy requires a highly personalized approach, with patients and physicians collaboratively weighing factors such as potential for deeper or longer remissions against toxicity profiles, treatment logistics (inpatient vs. outpatient administration), impact on daily activities, financial toxicity, caregiver burden and individual patient goals, with many emphasizing that this calculus shifts as patients progress through treatment lines—often prioritizing aggressive approaches earlier while placing greater emphasis on maintaining functionality and meaningful life experiences in later treatment stages.

Panelists discuss how physician-patient conversations about newer multiple myeloma therapies have evolved to include detailed discussions of potential benefits (higher response rates, novel mechanisms of action) alongside unique toxicity profiles (cytokine release syndrome with immunotherapies, neurotoxicity with CAR-T, skin/nail issues with GPRC5D-targeted agents), with patients sharing diverse experiences ranging from minimal side effects to significant complications that required hospitalization, emphasizing the importance of thorough preparation, proactive management strategies and realistic expectations when embarking on these innovative but potent treatment approaches.

Panelists discuss how ciltacabtagene autoleucel (cilta-cel) demonstrates superior outcomes compared to real-world physician’s choice of therapy in patients with late-line relapsed/refractory multiple myeloma (RRMM), with significantly higher response rates, deeper remissions, longer progression-free survival and potentially improved overall survival, though they acknowledge the challenges of cross-trial comparisons and emphasize the importance of considering patient-specific factors such as fitness, prior therapy exposure and treatment goals when weighing this one-time cellular therapy against sequential conventional approaches.

Panelists discuss how recent clinical trials have demonstrated promising outcomes in late-line relapsed/refractory multiple myeloma (RRMM) with bispecific antibodies targeting B-cell maturation antigen (BCMA) (teclistamab, talquetamab) and GPRC5D showing overall response rates of 60% to -70% even in heavily pretreated patients, while CAR-T cell therapies like ciltacabtagene autoleucel and idecabtagene vicleucel have produced deep responses with median progression-free survival extending beyond one year in some studies, and emerging combination approaches of these novel agents with traditional therapies are showing potential to overcome resistance mechanisms and improve durability of response.

Panelists discuss how managing the logistics of multiple myeloma treatment often requires a comprehensive support network, with patients describing complex arrangements for travel to specialized cancer centers, securing temporary lodging near treatment facilities, coordinating caregiver schedules to ensure continual support during intensive therapy periods, navigating insurance and financial assistance programs, and utilizing hospital social workers, patient advocacy organizations and online communities to access resources that ease the burden of treatment-related logistics.

Panelists discuss how patients and caregivers considering late-line multiple myeloma therapies must navigate practical considerations including lengthy hospital stays for CAR-T cell therapy (typically two to four weeks), insurance approval challenges, travel to specialized treatment centers, the potential need for caregivers to take extended leave from work, management of posttreatment monitoring requirements, eligibility criteria related to organ function and performance status and planning for potential complications such as cytokine release syndrome or neurological toxicities that might require urgent care access.

Panelists discuss how patient involvement in multiple myeloma treatment decisions has evolved from a physician-directed approach to a collaborative partnership, with many patients now actively participating through researching options, joining support groups, asking questions about efficacy and side effects, and working with their health care team to balance quality of life considerations with treatment goals, though the degree of engagement varies based on patient preference, health literacy and physician communication style.

Panelists discuss how treatment selection for late-line relapsed/refractory multiple myeloma (RRMM) balances multiple factors including patient fitness, prior therapy exposure, disease aggressiveness, side effect profiles, logistical considerations (with CAR-T requiring hospitalization while bispecifics can often be administered outpatient), financial accessibility and unique toxicity considerations (such as GPRC5D-targeting therapies affecting the skin and nails versus B-cell maturation antigen [BCMA]–targeting approaches), ultimately requiring a personalized approach weighing effectiveness against practical constraints on a patient-by-patient basis.

Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates and clinical trials of emerging agents, with treatment selection highly individualized based on prior therapies, resistance patterns and patient-specific factors like comorbidities, quality of life considerations and treatment goals.

Panelists discuss how multiple myeloma patients often navigate through numerous treatment regimens over their disease course, frequently cycling through five to 10 different therapeutic approaches since diagnosis, with the greatest challenges being management of cumulative side effects, emotional fatigue from repeated relapses and maintaining hope while facing increasingly limited options as they progress to late-line therapy.

Panelists discuss how the term “late-line” emerged organically in clinical practice to describe patients who had exhausted multiple treatment options, with most experts recalling its growing usage over the past decade as novel therapies expanded the treatment landscape and created a need to distinguish between patients with early and more heavily pretreated relapsed/refractory multiple myeloma (R/R MM).

Panelists discuss how the term "late-line" in relapsed/refractory multiple myeloma typically refers to patients who have progressed through multiple previous treatment regimens, indicating a more advanced disease state that has become resistant to several standard therapeutic approaches.